Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
February 26 2024 - 8:00AM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, today announced that management will participate in
one-on-one meetings at the Leerink Partners Global Biopharma
Conference 2024 being held in Miami, Florida on March 11-13, 2024.
Please contact your Leerink Partners representative to schedule
a one-on-one meeting.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical
company that was founded in 2018 with the mission to become a world
leader in the treatment of liver and viral diseases. Aligos’
strategy is to harness the deep expertise and decades of drug
development experience its team has in liver and viral diseases to
discover and develop potentially best in class therapeutics for
metabolic dysfunction-associated steatohepatitis (MASH) and viruses
with high unmet medical need such as chronic hepatitis B (CHB) and
coronaviruses.
CompanyJordyn TaraziVice President, Investor
Relations & Corporate Communications(650)
910-0427jtarazi@Aligos.com
MediaVeronica EamesLifeSci
Communicationsveames@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Apr 2024 to May 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From May 2023 to May 2024